8-K: GRI Bio Reports Positive Phase 2a Data for IPF Drug GRI-0621

GRI Bio, Inc. announced positive topline results from its Phase 2a clinical trial for GRI-0621 in idiopathic pulmonary fibrosis, demonstrating safety, tolerability, and disease-modifying potential.

Summary

• GRI-0621 met its primary endpoint, demonstrating it was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events.
• The study met secondary endpoints, showing improvement in serum biomarkers of collagen turnover, suggesting fibrosis resolution and alveolar basement membrane repair.
• GRI-0621 demonstrated increases in forced vital capacity (FVC) at both 6 and 12 weeks of treatment.
• 39% of GRI-0621 treated subjects experienced an increase in FVC at 12 weeks, contrasting with 80% of placebo subjects experiencing a decline.
• The safety profile was differentiated from existing treatments, with no increase in cough (0% in GRI-0621 arm vs. 25% in placebo) or gastrointestinal disorders (diarrhea 13% vs. 33% in placebo).
• Biomarkers indicated a shift from fibrogenic to fibrolytic collagen remodeling and induction of lung tissue repair mechanisms.
• Reductions in neutrophil and macrophage activity, and downregulation of genes associated with fibrosis, disease progression, and mortality were observed.

Sentiment

Score: 9

Explanation: The filing reports overwhelmingly positive topline Phase 2a clinical trial results for GRI-0621 in IPF, meeting both primary and secondary endpoints related to safety, tolerability, and disease-modifying biomarkers. Management commentary is highly optimistic, emphasizing the drug's potential to address unmet needs and create significant value. The data suggests a strong therapeutic profile and advancement potential.

Positives

• GRI-0621 was well tolerated over 12 weeks, with no drug-related severe or serious adverse events.
• No increase in GI issues when used with existing approved treatments.
• Improvements in serum biomarkers of collagen turnover (PRO-C6 decreased, C6M increased), suggesting fibrosis resolution and alveolar basement membrane repair.
• Increases in forced vital capacity (FVC) observed at 6 and 12 weeks of treatment.
• 39% of GRI-0621 treated subjects experienced an increase in FVC at 12 weeks, compared to 80% of placebo subjects experiencing a decline.
• Safety profile showed no increase in cough (0% vs 25% in placebo) or gastrointestinal disorders (diarrhea 13% vs 33% in placebo).
• Biomarkers of type IV collagen synthesis (PRO-C4) increased (+9% vs -2% in placebo), indicating lung tissue repair.
• Type IV collagen remodeling rate shifted from fibrolytic (-16% in placebo) to neutral (0% in GRI-0621), suggesting alveolar basement membrane repair.
• Significant reduction in DLK1 gene (-6.46 LogFC; FDR 0.0003), a gene involved in lung epithelial cell regeneration.
• Reductions in neutrophil and macrophage activity and downregulation of genes associated with fibrosis, disease progression, and mortality.

Negatives

• Common adverse events reported were dry skin, dry lips, muscle and joint pain, though these were not severe or serious.

Risks

• Inability to maintain the listing of the Company's common stock on The Nasdaq Capital Market and to comply with applicable listing requirements.
• Changes in applicable laws or regulations.
• Inability of the Company to raise financing in the future.
• Uncertainty regarding the success, cost, and timing of the Company's product development activities.
• Inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations.
• Inability of the Company to identify, in-license, or acquire additional technology.
• Inability of the Company to compete with other companies marketing or developing similar products and services.
• Uncertainty regarding the size and growth potential of the markets for the Company's products and services.
• Failure to achieve any milestones or receive any milestone payments under agreements.
• Inaccuracy in the Company's estimates regarding expenses, future revenue, capital requirements, and needs for and ability to obtain additional financing.
• Inability to protect and enforce its intellectual property portfolio, including any newly issued patents and its ability to obtain any expected patent term extensions, adjustments, exclusivities, or disclaimers.
• Actual results may differ from forward-looking statements due to inherent uncertainties, risks, and assumptions.

Future Outlook

GRI Bio believes GRI-0621 has disease-modifying potential that could go beyond slowing disease progression by directly impacting core drivers of IPF. The company is well-positioned to advance toward the next stage of development and believes GRI-0621 could represent a meaningful advance in the IPF treatment landscape, creating significant value for patients and shareholders.

Management Comments

• "Treatment of patients with IPF in the GRI-0621 Phase 2a trial was observed to be safe and well tolerated through the completion of the 12-week study." Toby Maher, MD, PhD, Professor of Clinical Medicine, Keck School of Medicine, USC Los Angeles.
• "Secondary endpoints related to the effect of GRI-0621 on biomarkers associated with disease progression provided evidence that GRI-0621 maintains a net anti-fibrotic effect compared to standard of care." Toby Maher, MD, PhD.
• "Lastly, FVC improved in patients treated with GRI-0621, with more patients experiencing an increase at 12 weeks than with standard of care. We look forward to watching the clinical advancement of GRI-0621 as a potential treatment for patients with IPF." Toby Maher, MD, PhD.
• "The positive Phase 2a results represent an important milestone for our IPF program and a compelling early signal of GRI-0621s disease-modifying potential." Marc Hertz, PhD, Chief Executive Officer of GRI Bio.
• "IPF remains one of the most devastating respiratory diseases, with limited treatment options and a significant need for therapies that can do more than slow decline and address the underlying biology of the disease." Marc Hertz, PhD.
• "In addition to a favorable safety and tolerability profile, GRI-0621 demonstrated meaningful improvement in biomarkers suggesting fibrosis resolution and repair of the alveolar basement membrane." Marc Hertz, PhD.
• "These results reinforce our belief in GRI-0621s differentiated mechanism and support its potential to go beyond slowing disease progression by directly impacting core drivers of IPF. With this mechanistic proof-of-biology in hand, we are well-positioned to advance toward the next stage of development." Marc Hertz, PhD.
• "We believe GRI-0621 could represent a truly meaningful advance in the IPF treatment landscape, with the potential to create significant value for patients and shareholders alike." Marc Hertz, PhD.

Industry Context

Idiopathic Pulmonary Fibrosis (IPF) is a devastating respiratory disease with limited treatment options that primarily slow decline. GRI-0621's positive Phase 2a data, particularly its differentiated safety profile and evidence of disease-modifying activity (fibrosis resolution, lung repair, FVC increases), positions it as a potentially significant advancement beyond current standard of care, which often comes with notable side effects like GI issues.

Comparison to Industry Standards

• GRI-0621's safety profile is differentiated from existing treatment options, showing no increase in cough (0% vs 25% in placebo) or gastrointestinal disorders (diarrhea 13% vs 33% in placebo), which are common side effects of approved IPF drugs like pirfenidone and nintedanib.
• The study demonstrated a net anti-fibrotic effect compared to standard of care, with improvements in biomarkers of collagen turnover (PRO-C6, C6M) suggesting fibrosis resolution.
• FVC improved in patients treated with GRI-0621, with more patients experiencing an increase at 12 weeks than with standard of care, where 80% of placebo subjects (on standard of care) experienced a decline.
• The observed shift in type IV collagen remodeling rate from fibrolytic in placebo-treated subjects to neutral in GRI-0621 treated subjects suggests an induction of lung tissue repair, a mechanism potentially superior to treatments that only slow disease progression.

Stakeholder Impact

• **Shareholders:** Potential for significant value creation due to positive clinical trial results for a lead drug candidate in a disease with high unmet need.
• **Patients:** Potential for a novel, well-tolerated therapeutic option for Idiopathic Pulmonary Fibrosis that may offer disease-modifying benefits beyond slowing decline.
• **Employees:** Positive clinical trial results validate the company's research and development efforts, potentially boosting morale and securing future projects.
• **Regulatory Authorities:** The positive data may facilitate future regulatory interactions and accelerate the development pathway for GRI-0621.

Next Steps

• Advance GRI-0621 toward the next stage of development for Idiopathic Pulmonary Fibrosis (IPF).

Key Dates

Recommendation

The positive topline Phase 2a data for GRI-0621 in Idiopathic Pulmonary Fibrosis (IPF) is a significant de-risking event for GRI Bio. The drug demonstrated excellent safety and tolerability, a crucial factor in IPF where existing treatments have notable side effects. More importantly, the data suggests disease-modifying potential through improvements in collagen turnover biomarkers and FVC increases, which could represent a substantial leap beyond current standard of care that primarily slows disease progression. Given the high unmet medical need in IPF and the potential for a differentiated, disease-modifying therapy, this outcome significantly enhances the drug's commercial prospects and the company's long-term value. While clinical development always carries risks, these strong early signals warrant a 'strong buy' recommendation for investors with a long-term horizon.

Keywords

Idiopathic Pulmonary Fibrosis, IPF, GRI-0621, Phase 2a Clinical Trial, Biotechnology, Immune Cell Modulators, Fibrotic Diseases, RAR Agonist, NKT Cells, Forced Vital Capacity, FVC, Biomarkers, Collagen Turnover, Alveolar Basement Membrane Repair, Clinical Data, Drug Development